SC
ANIP icon

Stephens Consulting’s ANI Pharmaceuticals ANIP Stock Holding History

Stephens Consulting’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$335 – 1239
2025
Q1 		$335 Buy
+5
New +$299 ﹤0.01% 1405

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Stephens Consulting's ANIP Position: Q2 2025 in Review

Stephens Consulting sold out of ANI Pharmaceuticals (ANIP) in Q2 2025, closing a stake of 5 shares — an estimated $335 sold.

Stephens Consulting first reported a position in ANIP in Q1 2025 and held it in 1 quarter. The position peaked at $335 in Q1 2025. 232 funds tracked by Wall St. Rank hold ANIP as of Q2 2025.

  • Stephens Consulting reported no remaining ANI Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 5 ANI Pharmaceuticals shares in Q2 2025, an estimated $335.
  • Stephens Consulting first reported a position in ANI Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's ANI Pharmaceuticals position peaked at $335 in Q1 2025.
  • 232 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.